Phil B.FontanarosaMD, Interim CoeditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephenLurieMD PhD, Fishbein FellowIndividualAuthor
Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.1999
In Reply: I appreciate that Dr Wilkinson may
disagree with my use of language; however, the offending phrases quoted in
her letter are taken out of context and appear more sensational than they
actually are. Her point that I wrote a factual inaccuracy is partially correct.
Current FDA policy does defer blood donations by individuals with classic
CJD. However, Wilkinson's statement that previous donations of blood and blood
components from such individuals are discarded is not fully accurate. On September
8, 1998, the FDA issued a change to its guidance governing blood donations
involving people with CJD.1 The guidance
involved plasma derivatives and indicated that such blood products would be
allowed even if they came from donors who subsequently develop classic CJD
(new variant CJD blood products would still be subject to retrieval, quarantine,
Mitka M. Transmissible Spongiform Encephalopathies and the US Blood Supply—Reply. JAMA. 1999;282(24):2301-2302. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-24-jbk1222